Skip to main content

Nanobiotix S.A 6-K, filed Oct 26, 2026

Nanobiotix S.A. (NBTX)

6-K 2026-10-26 For: 2026-10-24
View Original
Added on October 26, 2026

About this 6-K

Nanobiotix S.A filed this 6-K on October 26, 2026.

Nanobiotix reported final Phase 1 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant primary cutaneous melanoma. The overall response rate was 41.7% (10/24), including 4 complete responses, with median overall survival of 17.8 months. AI summary